Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21374651,extraction efficiency,The mean extraction efficiency was 88.6-107.2% of free and total warfarin.,Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21374651/),%,88.6-107.2,66107,DB01628,Etoricoxib
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,0.31,94872,DB01628,Etoricoxib
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,2.2,94873,DB01628,Etoricoxib
,17920584,ID(50),"In an adjuvant-induced arthritic model in rats, CS-706 suppressed foot swelling prophylactically with an ID(50) of 0.10 mg/kg/day, and decreased foot swelling in the established arthritis therapeutically in a dose range of 0.040 to 1.0 mg/kg/day.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),[mg] / [d·kg],0.10,94874,DB01628,Etoricoxib
,12638395,absolute bioavailability,Etoricoxib administered as a tablet was rapidly and completely absorbed and available; the absolute bioavailability was estimated to be 100%.,"Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638395/),%,100,101641,DB01628,Etoricoxib
,12638395,accumulation ratio,"The accumulation ratio averaged 2.1, and the corresponding accumulation t1/2 averaged 22 hours, supporting once-daily dosing.","Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638395/),,2.1,101642,DB01628,Etoricoxib
,12638395,accumulation t1/2,"The accumulation ratio averaged 2.1, and the corresponding accumulation t1/2 averaged 22 hours, supporting once-daily dosing.","Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638395/),h,22,101643,DB01628,Etoricoxib
,16013036,flow rate,The chromatographic separation was achieved by gradient elution consisting of 0.05 M formic acid (pH 3)-acetonitrile-methanol-water at a flow rate of 1.0 mL/min.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),[ml] / [min],1.0,105998,DB01628,Etoricoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,15.63,105999,DB01628,Etoricoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,17.20,106000,DB01628,Etoricoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,21.66,106001,DB01628,Etoricoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,24.95,106002,DB01628,Etoricoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,26.27,106003,DB01628,Etoricoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,30.24,106004,DB01628,Etoricoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,32.22,106005,DB01628,Etoricoxib
>,16013036,Absolute recovery,Absolute recovery was >83% from human plasma for all the analytes and IS.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),%,83,106006,DB01628,Etoricoxib
,12705971,m/z,The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1.,Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705971/),,359.2,125589,DB01628,Etoricoxib
,12705971,m/z,The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1.,Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705971/),,280.2,125590,DB01628,Etoricoxib
,12705971,m/z,The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1.,Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705971/),,189.0,125591,DB01628,Etoricoxib
,12705971,m/z,The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1.,Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705971/),,104.1,125592,DB01628,Etoricoxib
,22232850,Cmax,"After administering a single dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and reference products were 1.26 (0.33) and 1.29 (0.35) microg/ml for Cmax; 3.25 (2.64) and 2.63 (1.40) h for t(max); 29.63 (8.31) and 30.40 (5.85) h x microg/ml for AUC0-120; and 31.84 (10.97) and 33.00 (8.10) h x microg/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),[μg] / [ml],1.26,135509,DB01628,Etoricoxib
,22232850,Cmax,"After administering a single dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and reference products were 1.26 (0.33) and 1.29 (0.35) microg/ml for Cmax; 3.25 (2.64) and 2.63 (1.40) h for t(max); 29.63 (8.31) and 30.40 (5.85) h x microg/ml for AUC0-120; and 31.84 (10.97) and 33.00 (8.10) h x microg/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),[μg] / [ml],1.29,135510,DB01628,Etoricoxib
,22232850,t(max),"After administering a single dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and reference products were 1.26 (0.33) and 1.29 (0.35) microg/ml for Cmax; 3.25 (2.64) and 2.63 (1.40) h for t(max); 29.63 (8.31) and 30.40 (5.85) h x microg/ml for AUC0-120; and 31.84 (10.97) and 33.00 (8.10) h x microg/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),h,3.25,135511,DB01628,Etoricoxib
,22232850,t(max),"After administering a single dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and reference products were 1.26 (0.33) and 1.29 (0.35) microg/ml for Cmax; 3.25 (2.64) and 2.63 (1.40) h for t(max); 29.63 (8.31) and 30.40 (5.85) h x microg/ml for AUC0-120; and 31.84 (10.97) and 33.00 (8.10) h x microg/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),h,2.63,135512,DB01628,Etoricoxib
,22232850,AUC0-120,"After administering a single dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and reference products were 1.26 (0.33) and 1.29 (0.35) microg/ml for Cmax; 3.25 (2.64) and 2.63 (1.40) h for t(max); 29.63 (8.31) and 30.40 (5.85) h x microg/ml for AUC0-120; and 31.84 (10.97) and 33.00 (8.10) h x microg/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),[h·μg] / [ml],29.63,135513,DB01628,Etoricoxib
,22232850,AUC0-120,"After administering a single dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and reference products were 1.26 (0.33) and 1.29 (0.35) microg/ml for Cmax; 3.25 (2.64) and 2.63 (1.40) h for t(max); 29.63 (8.31) and 30.40 (5.85) h x microg/ml for AUC0-120; and 31.84 (10.97) and 33.00 (8.10) h x microg/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),[h·μg] / [ml],30.40,135514,DB01628,Etoricoxib
,22232850,AUC0-infinity,"After administering a single dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and reference products were 1.26 (0.33) and 1.29 (0.35) microg/ml for Cmax; 3.25 (2.64) and 2.63 (1.40) h for t(max); 29.63 (8.31) and 30.40 (5.85) h x microg/ml for AUC0-120; and 31.84 (10.97) and 33.00 (8.10) h x microg/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),[h·μg] / [ml],31.84,135515,DB01628,Etoricoxib
,22232850,AUC0-infinity,"After administering a single dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and reference products were 1.26 (0.33) and 1.29 (0.35) microg/ml for Cmax; 3.25 (2.64) and 2.63 (1.40) h for t(max); 29.63 (8.31) and 30.40 (5.85) h x microg/ml for AUC0-120; and 31.84 (10.97) and 33.00 (8.10) h x microg/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),[h·μg] / [ml],33.00,135516,DB01628,Etoricoxib
,22232850,t1/2,The mean t1/2 was found 27.99 (7.87) h and 29.84 (7.93) h for test and reference product respectively.,Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),h,27.99,135517,DB01628,Etoricoxib
,22232850,t1/2,The mean t1/2 was found 27.99 (7.87) h and 29.84 (7.93) h for test and reference product respectively.,Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232850/),h,29.84,135518,DB01628,Etoricoxib
,18840026,apparent volume of distribution,"Etoricoxib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 120 L in humans.",Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840026/),l,120,139735,DB01628,Etoricoxib
,18840026,elimination half-life,The elimination half-life of approximately 20 hours in healthy subjects enables once-daily dosing.,Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840026/),h,20,139736,DB01628,Etoricoxib
,30360014,flow rate,"Chromatography was performed on an Acquity UPLC HSS T3 column (1.8 μm, 50 × 2.1 mm), with a flow rate of 0.600 mL/min, using a gradient elution with acetonitrile and water which contained 2 mm ammonium acetate as the mobile phase.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),[ml] / [min],0.600,152578,DB01628,Etoricoxib
,30360014,peak concentration,"After a single oral dose of 120 mg, the main pharmacokinetic parameters of etoricoxib in fasted and fed groups were respectively as follows: peak concentration, 2364.78 ± 538.01 and 1874.55 ± 367.90 ng/mL; area under the concentration-time curve from 0 to 120 h, 44,605.53 ± 15,266.66 and 43,516.33 ± 12,425.91 ng h/mL; time to peak concentration, 2.00 and 2.50 h; and half-life, 24.08 ± 10.06 and 23.64± 6.72 h.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),[ng] / [ml],2364.78,152579,DB01628,Etoricoxib
,30360014,peak concentration,"After a single oral dose of 120 mg, the main pharmacokinetic parameters of etoricoxib in fasted and fed groups were respectively as follows: peak concentration, 2364.78 ± 538.01 and 1874.55 ± 367.90 ng/mL; area under the concentration-time curve from 0 to 120 h, 44,605.53 ± 15,266.66 and 43,516.33 ± 12,425.91 ng h/mL; time to peak concentration, 2.00 and 2.50 h; and half-life, 24.08 ± 10.06 and 23.64± 6.72 h.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),[ng] / [ml],1874.55,152580,DB01628,Etoricoxib
,30360014,area under the concentration-time curve from 0 to 120 h,"After a single oral dose of 120 mg, the main pharmacokinetic parameters of etoricoxib in fasted and fed groups were respectively as follows: peak concentration, 2364.78 ± 538.01 and 1874.55 ± 367.90 ng/mL; area under the concentration-time curve from 0 to 120 h, 44,605.53 ± 15,266.66 and 43,516.33 ± 12,425.91 ng h/mL; time to peak concentration, 2.00 and 2.50 h; and half-life, 24.08 ± 10.06 and 23.64± 6.72 h.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),[h·ng] / [ml],"44,605.53",152581,DB01628,Etoricoxib
,30360014,area under the concentration-time curve from 0 to 120 h,"After a single oral dose of 120 mg, the main pharmacokinetic parameters of etoricoxib in fasted and fed groups were respectively as follows: peak concentration, 2364.78 ± 538.01 and 1874.55 ± 367.90 ng/mL; area under the concentration-time curve from 0 to 120 h, 44,605.53 ± 15,266.66 and 43,516.33 ± 12,425.91 ng h/mL; time to peak concentration, 2.00 and 2.50 h; and half-life, 24.08 ± 10.06 and 23.64± 6.72 h.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),[h·ng] / [ml],"43,516.33",152582,DB01628,Etoricoxib
,30360014,time to peak concentration,"After a single oral dose of 120 mg, the main pharmacokinetic parameters of etoricoxib in fasted and fed groups were respectively as follows: peak concentration, 2364.78 ± 538.01 and 1874.55 ± 367.90 ng/mL; area under the concentration-time curve from 0 to 120 h, 44,605.53 ± 15,266.66 and 43,516.33 ± 12,425.91 ng h/mL; time to peak concentration, 2.00 and 2.50 h; and half-life, 24.08 ± 10.06 and 23.64± 6.72 h.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),h,2.00,152583,DB01628,Etoricoxib
,30360014,time to peak concentration,"After a single oral dose of 120 mg, the main pharmacokinetic parameters of etoricoxib in fasted and fed groups were respectively as follows: peak concentration, 2364.78 ± 538.01 and 1874.55 ± 367.90 ng/mL; area under the concentration-time curve from 0 to 120 h, 44,605.53 ± 15,266.66 and 43,516.33 ± 12,425.91 ng h/mL; time to peak concentration, 2.00 and 2.50 h; and half-life, 24.08 ± 10.06 and 23.64± 6.72 h.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),h,2.50,152584,DB01628,Etoricoxib
,30360014,half-life,"After a single oral dose of 120 mg, the main pharmacokinetic parameters of etoricoxib in fasted and fed groups were respectively as follows: peak concentration, 2364.78 ± 538.01 and 1874.55 ± 367.90 ng/mL; area under the concentration-time curve from 0 to 120 h, 44,605.53 ± 15,266.66 and 43,516.33 ± 12,425.91 ng h/mL; time to peak concentration, 2.00 and 2.50 h; and half-life, 24.08 ± 10.06 and 23.64± 6.72 h.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),h,24.08,152585,DB01628,Etoricoxib
,30360014,half-life,"After a single oral dose of 120 mg, the main pharmacokinetic parameters of etoricoxib in fasted and fed groups were respectively as follows: peak concentration, 2364.78 ± 538.01 and 1874.55 ± 367.90 ng/mL; area under the concentration-time curve from 0 to 120 h, 44,605.53 ± 15,266.66 and 43,516.33 ± 12,425.91 ng h/mL; time to peak concentration, 2.00 and 2.50 h; and half-life, 24.08 ± 10.06 and 23.64± 6.72 h.",Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30360014/),h,23.64,152586,DB01628,Etoricoxib
,15473012,Retention times,"Retention times of etoricoxib and valdecoxib were 1.05 and 1.08 min, respectively.",A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473012/),min,1.05,167007,DB01628,Etoricoxib
,15473012,Retention times,"Retention times of etoricoxib and valdecoxib were 1.05 and 1.08 min, respectively.",A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473012/),min,1.08,167008,DB01628,Etoricoxib
,32303303,maximum concentration,The results show that the drug reached a maximum concentration of 505.2 ± 67.8 ng/mL in 48 minutes after administration.,Detection and Pharmacokinetics of Etoricoxib in Thoroughbred Horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32303303/),[ng] / [ml],505.2,167757,DB01628,Etoricoxib
,32303303,elimination half-life,The elimination half-life was calculated to be 10.20 ± 1.30 hours.,Detection and Pharmacokinetics of Etoricoxib in Thoroughbred Horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32303303/),h,10.20,167758,DB01628,Etoricoxib
<,20052461,lag times,Individual CSF lag times with respect to (50%) peak plasma concentration were </=2 h in all but one case (median: 1 h).,"Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20052461/),h,2,171729,DB01628,Etoricoxib
,20052461,lag times,Individual CSF lag times with respect to (50%) peak plasma concentration were </=2 h in all but one case (median: 1 h).,"Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20052461/),h,1,171730,DB01628,Etoricoxib
,12527704,plasma clearance,"Following the i.v. dose, the plasma clearance was 57 ml/min, and the harmonic mean half-life was 24.8 h.","Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527704/),[ml] / [min],57,211282,DB01628,Etoricoxib
,12527704,half-life,"Following the i.v. dose, the plasma clearance was 57 ml/min, and the harmonic mean half-life was 24.8 h.","Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527704/),h,24.8,211283,DB01628,Etoricoxib
,12527704,absolute bioavailability,"The oral dose, administered as a solution in polyethylene glycol-400, was well absorbed (absolute bioavailability of approximately 83%).","Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527704/),%,83,211284,DB01628,Etoricoxib
,12527704,Total recovery of radioactivity,"Total recovery of radioactivity in the excreta was 90% (i.v.) and 80% (p.o.), with 70% (i.v.) and 60% (p.o.) excreted in urine and 20% in feces after either route of administration.","Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527704/),%,90,211285,DB01628,Etoricoxib
,12527704,Total recovery of radioactivity,"Total recovery of radioactivity in the excreta was 90% (i.v.) and 80% (p.o.), with 70% (i.v.) and 60% (p.o.) excreted in urine and 20% in feces after either route of administration.","Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527704/),%,80,211286,DB01628,Etoricoxib
,12527704,Total recovery of radioactivity,"Total recovery of radioactivity in the excreta was 90% (i.v.) and 80% (p.o.), with 70% (i.v.) and 60% (p.o.) excreted in urine and 20% in feces after either route of administration.","Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527704/),%,70,211287,DB01628,Etoricoxib
,12527704,Total recovery of radioactivity,"Total recovery of radioactivity in the excreta was 90% (i.v.) and 80% (p.o.), with 70% (i.v.) and 60% (p.o.) excreted in urine and 20% in feces after either route of administration.","Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527704/),%,60,211288,DB01628,Etoricoxib
,12527704,Total recovery of radioactivity,"Total recovery of radioactivity in the excreta was 90% (i.v.) and 80% (p.o.), with 70% (i.v.) and 60% (p.o.) excreted in urine and 20% in feces after either route of administration.","Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527704/),%,20,211289,DB01628,Etoricoxib
,29670410,AUC0-72h,"After a single-dose administration of etoricoxib 120 mg film-coated tablet, the mean (SD) values for the AUC0-72h and Cmax of the test drug were 45913.42 (13142.19) ng·h/mL and 3155.93 (752.81) ng/mL, respectively; the values for the reference drug were 44577.20 (13541.85) ng·h/mL and 2915.13 (772.81) ng/mL, respectively.",Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29670410/),[h·ng] / [ml],45913.42,236603,DB01628,Etoricoxib
,29670410,AUC0-72h,"After a single-dose administration of etoricoxib 120 mg film-coated tablet, the mean (SD) values for the AUC0-72h and Cmax of the test drug were 45913.42 (13142.19) ng·h/mL and 3155.93 (752.81) ng/mL, respectively; the values for the reference drug were 44577.20 (13541.85) ng·h/mL and 2915.13 (772.81) ng/mL, respectively.",Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29670410/),[h·ng] / [ml],44577.20,236604,DB01628,Etoricoxib
,29670410,Cmax,"After a single-dose administration of etoricoxib 120 mg film-coated tablet, the mean (SD) values for the AUC0-72h and Cmax of the test drug were 45913.42 (13142.19) ng·h/mL and 3155.93 (752.81) ng/mL, respectively; the values for the reference drug were 44577.20 (13541.85) ng·h/mL and 2915.13 (772.81) ng/mL, respectively.",Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29670410/),[ng] / [ml],3155.93,236605,DB01628,Etoricoxib
,29670410,Cmax,"After a single-dose administration of etoricoxib 120 mg film-coated tablet, the mean (SD) values for the AUC0-72h and Cmax of the test drug were 45913.42 (13142.19) ng·h/mL and 3155.93 (752.81) ng/mL, respectively; the values for the reference drug were 44577.20 (13541.85) ng·h/mL and 2915.13 (772.81) ng/mL, respectively.",Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29670410/),[ng] / [ml],2915.13,236606,DB01628,Etoricoxib
,32606658,EE%,M14 system was nano-spherical particles of 488 nm size possessing promising yield% (63.5%) and EE% (91.2%).,Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606658/),%,91.2,245104,DB01628,Etoricoxib
,32606658,percentage drug released,"The percentage drug released after 2, 4 and 12 hours were 43.41%, 47.34 and 64.96%, respectively.",Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606658/),%,43.41,245105,DB01628,Etoricoxib
,32606658,percentage drug released,"The percentage drug released after 2, 4 and 12 hours were 43.41%, 47.34 and 64.96%, respectively.",Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606658/),%,47.34,245106,DB01628,Etoricoxib
,32606658,percentage drug released,"The percentage drug released after 2, 4 and 12 hours were 43.41%, 47.34 and 64.96%, respectively.",Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606658/),%,64.96,245107,DB01628,Etoricoxib
,32606658,Tmax,"Significant (p < 0.05) differences between the pharmacokinetic parameter of E-M14C in comparison with the commercial product were revealed with a delay in Tmax (from 2.5h to 6h), a prolongation in MRT0-∞ (from 24.4h to 34.7h) and an increase in the relative oral bioavailability (4.23 folds).",Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606658/),h,2.5,245108,DB01628,Etoricoxib
,32606658,Tmax,"Significant (p < 0.05) differences between the pharmacokinetic parameter of E-M14C in comparison with the commercial product were revealed with a delay in Tmax (from 2.5h to 6h), a prolongation in MRT0-∞ (from 24.4h to 34.7h) and an increase in the relative oral bioavailability (4.23 folds).",Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606658/),h,6,245109,DB01628,Etoricoxib
,32606658,MRT0-∞,"Significant (p < 0.05) differences between the pharmacokinetic parameter of E-M14C in comparison with the commercial product were revealed with a delay in Tmax (from 2.5h to 6h), a prolongation in MRT0-∞ (from 24.4h to 34.7h) and an increase in the relative oral bioavailability (4.23 folds).",Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606658/),h,24.4,245110,DB01628,Etoricoxib
,32606658,MRT0-∞,"Significant (p < 0.05) differences between the pharmacokinetic parameter of E-M14C in comparison with the commercial product were revealed with a delay in Tmax (from 2.5h to 6h), a prolongation in MRT0-∞ (from 24.4h to 34.7h) and an increase in the relative oral bioavailability (4.23 folds).",Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606658/),h,34.7,245111,DB01628,Etoricoxib
,27086319,highest measured concentration (C max),"In CSF the highest measured concentration (C max) of dexketoprofen was 4.0 (median) ng/mL (minimum-maximum 1.9-13.9) and time to the highest concentration (t max) 3 h (2-5), and for etoricoxib C max 73 ng/mL (36-127) and t max 5 h (1-24), respectively.",The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086319/),[ng] / [ml],4.0,251471,DB01628,Etoricoxib
,27086319,time to the highest concentration (t max),"In CSF the highest measured concentration (C max) of dexketoprofen was 4.0 (median) ng/mL (minimum-maximum 1.9-13.9) and time to the highest concentration (t max) 3 h (2-5), and for etoricoxib C max 73 ng/mL (36-127) and t max 5 h (1-24), respectively.",The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086319/),h,3,251472,DB01628,Etoricoxib
,27086319,C max,"In CSF the highest measured concentration (C max) of dexketoprofen was 4.0 (median) ng/mL (minimum-maximum 1.9-13.9) and time to the highest concentration (t max) 3 h (2-5), and for etoricoxib C max 73 ng/mL (36-127) and t max 5 h (1-24), respectively.",The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086319/),[ng] / [ml],73,251473,DB01628,Etoricoxib
,27086319,t max,"In CSF the highest measured concentration (C max) of dexketoprofen was 4.0 (median) ng/mL (minimum-maximum 1.9-13.9) and time to the highest concentration (t max) 3 h (2-5), and for etoricoxib C max 73 ng/mL (36-127) and t max 5 h (1-24), respectively.",The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27086319/),h,5,251474,DB01628,Etoricoxib
,18823299,T(max),"The median (range) for digoxin T(max) (h) values with etoricoxib and placebo were 0.5 (0.5, 1.5) and 1.0 (0.5, 1.5), respectively.",Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823299/),h,0.5,255102,DB01628,Etoricoxib
,18823299,T(max),"The median (range) for digoxin T(max) (h) values with etoricoxib and placebo were 0.5 (0.5, 1.5) and 1.0 (0.5, 1.5), respectively.",Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823299/),h,1.0,255103,DB01628,Etoricoxib
,15220011,time to onset of analgesia,"The median time to onset of analgesia was 24 minutes for etoricoxib 120, 180, and 240 mg, and 30 minutes for etoricoxib 60 mg and ibuprofen.","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),min,24,266197,DB01628,Etoricoxib
,15220011,time to onset of analgesia,"The median time to onset of analgesia was 24 minutes for etoricoxib 120, 180, and 240 mg, and 30 minutes for etoricoxib 60 mg and ibuprofen.","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),min,30,266198,DB01628,Etoricoxib
>,15220011,duration of analgesic effect,"The duration of analgesic effect was >24 hours for etoricoxib 120, 180, and 240 mg, and 12.1 hours for etoricoxib 60 mg.","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),h,24,266199,DB01628,Etoricoxib
,15220011,duration of analgesic effect,"The duration of analgesic effect was >24 hours for etoricoxib 120, 180, and 240 mg, and 12.1 hours for etoricoxib 60 mg.","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),h,12.1,266200,DB01628,Etoricoxib
,15220011,duration of effect,"The duration of effect was significantly longer with all 4 etoricoxib doses compared with ibuprofen (10.1 hours; P < 0.05 etoricoxib 60 mg; < or = 0.001etoricoxib 120, 180, and 240 mg) and compared with placebo (2.1 hours; P < = 0.001).","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),h,10.1,266201,DB01628,Etoricoxib
,15220011,duration of effect,"The duration of effect was significantly longer with all 4 etoricoxib doses compared with ibuprofen (10.1 hours; P < 0.05 etoricoxib 60 mg; < or = 0.001etoricoxib 120, 180, and 240 mg) and compared with placebo (2.1 hours; P < = 0.001).","Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220011/),h,2.1,266202,DB01628,Etoricoxib
